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Serotype 1 is one of the most common causes of pneumococcal disease worldwide. Pneumococcal protein
vaccines are currently being developed as an alternate intervention strategy to pneumococcal conjugate
vaccines. Pre-requisites for an efficacious pneumococcal protein vaccine are universal presence and min-
imal variation of the target antigen in the pneumococcal population, and the capability to induce a robust
human immune response. We used in silico analysis to assess the prevalence of seven protein vaccine
candidates (CbpA, PcpA, PhtD, PspA, SP0148, SP1912, SP2108) among 445 serotype 1 pneumococci from
26 different countries, across four continents. CbpA (76%), PspA (68%), PhtD (28%), PcpA (11%) were not
universally encoded in the study population, and would not provide full coverage against serotype 1.
PcpA was widely present in the European (82%), but not in the African (2%) population. A multi-valent
vaccine incorporating CbpA, PcpA, PhtD and PspA was predicted to provide coverage against 86% of
the global population. SP0148, SP1912 and SP2108 were universally encoded and we further assessed
their predicted amino acid, antigenic and structural variation. Multiple allelic variants of these proteins
were identified, different allelic variants dominated in different continents; the observed variation was
predicted to impact the antigenicity and structure of two SP0148 variants, one SP1912 variant and four
SP2108 variants, however these variants were each only present in a small fraction of the global popula-
tion (<2%). The vast majority of the observed variation was predicted to have no impact on the effica-
ciousness of a protein vaccine incorporating a single variant of SP0148, SP1912 and/or SP2108 from S.
pneumoniae TIGR4. Our findings emphasise the importance of taking geographic differences into account
when designing global vaccine interventions and support the continued development of SP0148, SP1912
and SP2108 as protein vaccine candidates against this important pneumococcal serotype.
 2017 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/)., Malawi.
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Streptococcus pneumoniae is a human nasopharyngeal commen-
sal that can invade normally sterile sites to cause invasive pneu-
mococcal disease (IPD), including bacteraemia and meningitis [1].
Annually, IPD accounts for more than 800,000 deaths in children
under five years old, mainly in the developing world [2,3].
There are >90 pneumococcal serotypes, each of which produce a
biochemically distinct capsular polysaccharide (CPS) and vary in
propensity to cause invasive disease [4]. Serotype 1 is one of the
most common causes of IPD worldwide. In Africa, it is responsible
for 11.7% of all IPD cases [5]. In contrast to other serotypes, sero-
type 1 is associated with outbreaks in closed communities [6]
and lethal meningitis outbreaks in West Africa [7,8]. The high bur-
den of serotype 1 IPD emphasizes the need for an effective vaccine
against this serotype. The 10- and 13-valent pneumococcal conju-
gate vaccines (PCV10 and PCV13) have been rolled out across
Africa with support from the GAVI alliance (www.gavi.org), both
formulations incorporate serotype 1, however the full impact of
these vaccines across the continent is not yet known [9].
A major limitation of PCVs is they only elicit protective antibod-
ies against the serotypes included in the vaccine formulation. As a
result non-vaccine serotypes can increase in frequency in IPD and
carriage post PCV introduction, as observed following PCV7 intro-
duction in the USA [10]. Furthermore, vaccine serotypes can
alter/exchange portions of their CPS locus to escape host antibod-
ies, a phenomenon known as ‘capsule switching’ [11]. The ability of
pneumococci to continuously alter their genotype and thereby
evade vaccine selective pressure is often referred to as ‘Red Queen’
dynamics; it has been suggested that Red Queen dynamics must be
taken into account when designing new vaccine strategies [12].
Alternative serotype-independent protein vaccines, which avoid
Red Queen dynamics by targeting widely distributed pneumococ-
cal proteins are therefore in development based on conserved,
[13]. PATH (www.path.org) is committed to develop protein-
based vaccines tailored for the developing world and has high-
lighted seven promising candidates: choline binding protein
(CbpA), pneumococcal-binding protein A (PcpA), pneumococcal
histidine triad protein (PhtD), pneumococcal surface protein C
(PspC), SP0148 a putative ABC transporter protein, SP1912 a puta-
tive thioredoxin and SP2108 a putative sugar ABC transporter sub-
strate binding protein. CbpA has been shown to mediate antibody
protection against pneumococcal pneumonia, as has PspC [14].
PcpA and PhtD exhibited promising immunogenicity and safety
profiles in monovalent and bivalent formulations in phase 1 clini-
cal trials [15]. A trivalent formulation of SP0148, SP1912, and
SP2108 was reported to be safe and immunogenic and to elicitTable 1
In silico PCR primers used to identify genes encoding S. pneumoniae protein vaccine candi
Target gene Primer pair*
cbpA 50-GGAAGTCAGTATTAACTAGTTATATTAGGTT
30- TGTTTATTTCCTTCTATATTTTTTCTTTAAC
pcpA 50-TCAGAATGATTAGATTTAGCTAATGGATACC
30-TTTAAATTTCCTTACATATTTATTTTCTAAT
phtD 50-TTCTAGCAGAAGAATTAAAGTGAGGAAAGAA
30-GTAAAATGAATGGAGCATATTTTATGGAGAA
pspA 50AAATGACTATCAGAAAAGAGGTAAATTTAGA
30AGCCGATTAAATTAAATCATGTTAAGAACAT
sp0148 50-GGAAGTCAGTATTAACTAGTTATATTAGGTT
30-TGTTTATTTCCTTCTATATTTTTTCTTTAAC
sp1912 50-ATGCTAATTCTTCTAAACTTGCTGGCTGTAT
30-TACCATTCATTTTAACACAAAAAAGGCTTCA
sp2108 50-AAACTTGCTATTCTTTGGGAGGAATACACTA
30-TGTTTATTTCCTTCTATATTTTTTCTTTAAC
* Derived from the 31 nucleotides flanking the 30 and 50 of the target gene in the refestrong T helper 17 cells (TH17) responses in healthy volunteers in
phase 1 clinical trials [16,17].
In addition to being immunogenic, a requisite for a protein vac-
cine candidate is that the selected antigen(s) is widely distributed
in the target pneumococcal population. Variation in the amino acid
sequence of the protein has the potential to reduce the immuno-
genicity of a vaccine based on only a single variant. Hence an addi-
tional requisite is minimal genomic diversity within the selected
protein among clinical isolates. Here we consider seven protein
vaccine candidates currently under investigation by PATH in a glo-
bal collection of serotype 1 pneumococci, with a specific focus on
African isolates, in order to assess their suitability as future vaccine
candidates against this important serotype. We describe their
prevalence’s and further investigate the sequence-based prediction
of antigenic and structural diversity of three of them.
2. Methods
2.1. Isolate collection
The collection was previously subjected to Illumina sequencing
and genome assembly by the Pneumococcal African Genomics
Consortium (http://www.pagegenomes.org) (Supplementary
Table S1); a detailed sampling description can be found elsewhere
[18]. Isolates were recovered between 1994 and 2009 prior to the
widespread introduction of PCV in Africa and were collected to
encompass diversity with respect to geographic location, isolation,
clinical source (carriage and disease) and patient age.
2.2. Protein identification
Digital primers were designed to ‘bind’ to the flanking 31
nucleotides from 50 and 30 ends of each vaccine candidate gene
(Table 1), in silico PCR was performed using Perl scripts to search
each gene primer pair against the assembled genomes and allowed
for sequence variation in the ‘binding sites’. Nucleotide sequence
between each primer pair was translated into amino acid
sequence.
2.3. Variant determination
Amino acid sequences for SP0148, SP1912 and SP2108 were
independently aligned, to identify different variants at the protein
level. Each alignment was compared to the reference sequence
SP0148 TIGR4 (Accession: NP_344690), SP1912 TIGR4 (Accession:
ABJ54543) or SP2108 TIGR4 (Accession: ABJ55468); TIGR4 genes
coding for these proteins where initially cloned in Escherichia colidates in a global dataset of 445 serotype 1 isolates.
NCBI reference accession Genomic coordinates of the gene
NC_011900.1 896104. . .898620
NC_011900.1 2108466. . .2110451
NC_011900.1 119801. . .121630
NC_017593.1 2170171. . .2172795
NC_011900.1 2076464. . .2077735
NC_011900.1 1882330. . .1882620
NC_011900.1 150062. . .150892
rence genome.
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was assigned a unique numerical designation.
2.4. Antigenicity plots
Antigenicity patterns of SP0148, SP1912 and SP2108 were mea-
sured using the Hopps and Woods hydrophilicity scale (http://
web.expasy.org/protscale/) with a window size of 9, which assigns
a numerical hydrophilicity value to each amino acid and takes a
moving average along the peptide chain. The point of highest local
average hydrophilicity is consistently located in, or immediately
adjacent to an antigenic determinant [19]. The hydrophilicity val-
ues were used to generate antigenicity plots for each variant. Anti-
genicity plots with different amplitudes/number of peak
hydrophilicity points from the TIGR4 reference were considered
to be ‘antigenically different’.
2.5. Prediction of functional effects of variations
PROVEAN [20], PhD-SNP (http://snps.biofold.org/phd-snp/) and
PolyPhen-2 [21] were used to predict the impact of amino acid
substitutions. PROVEAN includes bacterial protein analysis; PhD-
SNP and PolyPhen-2 were developed to analyse human proteins;
thus only the PROVEAN results alone or the consensus result of
three programs was considered (Supplementary Table S2).
2.6. Homology modelling
TIGR4 reference sequences of SP0148, SP1912 and SP2108 were
used as queries in HHpred search for template identification [22].
For SP0148, protein structure 4EQ9; for SP1912 2M70; for
SP2108 2XD3 was identified. Modelling was performed by MODEL-
LER v9.16 using very slow refinement option. 100 models were
generated per case, and best models were selected according to
DOPE Z scores.
3. Results
3.1. Distribution of protein vaccine candidates
An effective protein vaccine candidate needs to be based on a
protein antigen that is widely distributed within the population.Fig. 1. Global percentage distribution of seven S. pneumoniae protein vaccine candidates a
(n = 28) and South America (n = 17), expressed as a percentage of the number of sampleWe therefore assessed the prevalence of seven-protein vaccine
candidates within a global serotype 1 collection (n = 445) (Fig. 1).
The African collection included 324 isolates, the non-African col-
lection included 121 isolates spanning three continents (Asia = 76,
Europe = 28, South America = 17). SP0148, SP1912 and SP2108
were identified in 100% (445/445), CbpA was identified in 76%
(340/445), PspA in 68% (305/445), PhtD in 28% (125/445) and PcpA
in 11% (49/445) of the study population. A monovalent protein vac-
cine based on CbpA, PcpA, PhtD or PspA would only provide partial
coverage against serotype 1 globally. PspA was identified in 76%
(58/76) of Asian isolates but only 41% (7/17) of South American
isolates. Likewise, PcpA was identified in 82% (23/28) of the Euro-
pean isolates, but only 2% (6/324) and 14% (11/76) of the African
and Asian isolates respectively.
3.2. Multi-valent vaccine coverage
Vaccines based on a combination of two or more proteins have
been proposed to increase protein vaccine coverage. Table 2 shows
the predicted coverage of combinations of CbpA, PcpA, PhtD and/or
PspA against serotype 1 pneumococci. A combination of all four
proteins would provide the highest coverage (86%) against sero-
type 1 pneumococci globally, only 2% higher than the predicated
coverage from a tri-valent combination CbpA/PcpA/PspA (82%).
Of the bi-valent combinations, CbpA/PcpA (79%) would provide
the highest and PcpA/PhtD (37%) the lowest overall predicted glo-
bal coverage.
3.3. Diversity of vaccine candidates
The diversity of the protein vaccine candidates that showed
100% distribution, SP0148, SP1912 and SP2108, was investigated
(Fig. 2, Table 3). Based on amino acid sequence variation, six vari-
ants of SP0148 were identified, all 276 amino acids in length.
SP0148 variant-1 was the most dominant, present in 100%
(324/324), 84% (64/76) and 47% (8/17) of the African, Asian and
South American isolates respectively. Variant-1 was not identified
in the European population; SP0148 variant-2 and -3 were present
in 75% (21/28) and 25% (7/28) of the European population, respec-
tively. In contrast to the dominance of a single variant in the Afri-
can serotype 1 population, SP0148 showed a high degree of
heterogeneity in the Asian serotype 1 isolates; all 6 variants weremong serotype 1 pneumococci recovered from Asia (n = 76), Africa (n = 324), Europe
s submitted from each continent.
Table 2
The predicted % coverage of multi-valent protein vaccine based on combinations of two or more of CbpA, PcpA, PhtD and PspA would provide against serotype 1 pneumococci by
continent and also globally.
Protein combination Asia (n = 76) Africa (n = 324) Europe (n = 28) South America (n = 17) Global (n = 445)
CbpA, PcpA 86 75 96 82 79
CbpA, PhtD 86 75 96 82 78
CbpA, PspA 84 80 68 65 79
PcpA, PhtD 29 34 82 59 37
PhtD, PspA 78 77 75 47 76
CbpA, PcpA, PhtD 84 83 96 82 84
CbpA, PcpA, PspA 84 80 96 82 82
PcpA, PhtD, PspA 80 78 96 82 80
CbpA, PcpA, PhtD, PspA 86 85 96 82 86
Fig. 2. Global percentage distribution of amino acid variants of three S. pneumoniae protein vaccine candidates; [A] SP0148, [B] SP1912 and [C] SP2108. These three protein
candidates were present in all serotype 1 pneumococci within the global serotype 1 study population.
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Table 3
Amino acid variations in three S. pneumoniae protein vaccine candidates [A] SP0148, [2] SP1912 and [C] SP2108, among a global dataset of serotype 1 pneumococci. The tables show the amino acid residues at which substitutions have
been identified when using the corresponding protein sequences from Streptococcus pneumoniae TIGR4 as a reference. ‘.’ Indicates that a residue is identical to the TIGR4 reference sequence. Residues highlighted in grey indicate regions
where the amino acid variation is predicted to result in a change to the antigenicity profile of the protein. Underlined residues indicate that the amino acid variation is predicted to be deleterious to the protein. Amino acid numbering
starts at the translation site (the methionine) of the TIGR4 reference sequences.
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between 91.3% (variant-3) and 99.3% amino acid (variant-2) iden-
tity with SP0148 TIGR4.
Only two variants of SP1912 were identified, both 99 amino
acids in length. With the exception of a subset of the Asian isolates,
all study isolates possessed an SP1912 variant-1 with 100% amino
acid identify to SP1912 TIGR4. Variant-2 was identified in 15%
(11/76) of the Asian isolates, 2% (11/445) of the overall study pop-
ulation showed 97% identity to SP1912 TIGR4.
Twelve variants of SP2108 were identified, all 426 amino acids
in length. Variant-1 exhibited 100% identity to SP2108 TIGR4. All of
the remaining variants exhibited above 99.3% identity to SP2108
TIGR4. SP2108 variant-1 was the most widely distributed variant,
present in the African (82%. 272/332) and Asian (63%, 48/76) pop-
ulations but not present in the European or South American iso-
lates. Variant-3 was identified in the European (86%, 24/28) and
South American (71%, 12/17) populations but not in any of the Afri-
can or Asian.
3.4. Functional effects of variation
The impact of the observed amino acid substitutions on protein
structure/function and antigenicity was next assessed, to predict
potential vaccine efficacy (Fig. 3, Table 2). The crystal structure ofFig. 3. Comparison of the hydrophobicity plots of amino acid variants of three S. pneumo
axis represents hydrophilicity values; the y axis indicates amino acid number. The regio
data line represents the antigenicity values for each of the three proteins from the TIGRGshT (ABC transporter glutathione-binding protein) (PDB ID:
4EQ9) was used to model SP0148 variant-3. This protein exhibited
97% sequence identity to TIGR4 SP0148 between residues 31–266.
Variant-3 was selected for modelling because it included 83.3%
(25/30) of all the substitutions observed within the other variants.
All of the substitutions identified in variant-3, in addition to 5 sub-
stitutions identified within the other SP0148 variants, were
mapped to the model structure (Table 3A, Fig. 4A). A122V and
N124D, identified in variant-3 only, resulted in the side chains of
these residues to face inwards, whilst they faced outward in the
reference protein. Furthermore, A122V and N124D led to a switch
from hydrophobicity to hydrophilicity at residues 117–128 relative
to TIGR4 SP0148 (Table 2, Fig. 3). Given that peak regions of
hydrophilicity are hypothesised to be antigenic, variant-3 may
exhibit increased antigenicity relative to TIGR4. D199A identified
in SP0148 variant-4 was the only substitution predicted to be dele-
terious by all three SNP analysis tools (Supplementary Table S1). It
is likely that pneumococci encoding this variant do not express a
functional SP0148 protein. Therefore a monovalent vaccine based
on SP0148 TIGR4 may not confer protection against pneumococci
encoding SP0148 variant-4. Variant-4 was identified in 5% (4/76)
of the Asian isolates, or <1% of the global population (4/448).
Protein NP_346341.1 from S. pneumoniae (PDB ID: 3M7O) with
unknown function exhibited 100% sequence identity to SP1912niae protein vaccine candidates [A] SP0148, [B] SP1912 and [C] SP2108. The vertical
n of maximal hydrophilicity in each plot is likely to be the antigenic site. The black
4 reference.
Fig. 4. Cartoon representations of the protein structure of [A] SP0148 [B] SP1912
and [C] SP2108. [A] SP0148 – The locations of the variant-3 amino acid substitu-
tions are mapped into the structure; green for the potential deleterious variations
detected by PROVEAN only (also indicated by their residue numbers); purple for the
non-deleterious variations. Additionally, the position of D199A variation, detected
in variant 5 and agreed as deleterious by 3 SNP programs, is colored in turquoise. [B]
SP1912 – Variant-1 and variant-2. The locations of the amino acid variations are
mapped into the structures, and indicated by residue numbers and purple
colouring. [C] SP2018 – The locations of the amino acid substitutions are mapped
into the structure in two different colours; green for potential deleterious variations
(also indicated by their residue numbers); purple for the rest.
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utilised for homology modelling. Three substitutions were identi-
fied in variant-2 relative to variant-1; R33H, E44A and V72L.
R33H and V72L were not predicted to affect the protein structure
(Fig. 4B). E44A was located in the helical structure of the protein;
alanine has the propensity to form alpha helices and it retains
the backbone structure as well as beta carbon, thus E44A may
impact the interaction of variant-2 with antibodies. Variant-2
SP1912 exhibited slightly reduced hydrophilicity peaks at three
regions relative to the SP1912 TIGR4, each corresponding to a three
amino acid substitution, 27–35 (R33H), 38–46 (E44A) and 65–73
(V72L). SP1912 variant-2 was only identified in European isolates
(15%, 11/76) representing 2% (11/445) of the isolates globally.
A maltose/maltodextrin-binding protein from S. pneumoniae
TIGR4 (PDB ID: 2XD3), 98% identical to the SP2108 TIGR4 protein
for the residues 43–423, was used to model the SP2108 variants
(Fig. 4C). All SNP analysis tools agreed that D88G variant-8,
D103G variant-7 and L230R were deleterious. PROVEAN and
Polyphen-2 further identified D326G variant-9 as deleterious.
These substitutions in variant-7, -8, -9, -12 could lead to non-
functional proteins, so that a monovalent vaccine based on
SP1912 TIGR4 may not confer protection against pneumococci
encoding these variants. These variants were however only identi-
fied in a single study isolate (variant-7, -9 and -12 in African iso-
lates; variant-8 in a European isolate). D326G variant-9 led to a
large decrease in hydrophilicity in residues 322–330. L230R
variant-12 was associated with an increase in hydrophilicity in
residues 200–209. However given that these regions do not repre-
sent hydrophilic peaks in SP2108 TIGR4, it is unlikely that these
allelic variants exhibit altered antigenicity to the reference
sequence.4. Discussion
The first requisite for a pneumococcal protein vaccine is wide
distribution in the target population. We first investigated the
prevalence of seven of the most promising vaccine protein candi-
dates (PhtD, PcpA, CbpA, PspC, SP2108, SP1912 and SP0148) in
the largest sequenced collection of a single serotype to date; 445
serotype 1 pneumococci isolated from four different continents,
with a specific focus on isolates recovered from Africa, where ser-
otype 1 arguably causes the greatest disease burden. PcpA, CbpA,
PhtD and PspC were not present in all of the serotype 1 population.
Furthermore, there was variation in the prevalence of these pro-
teins within serotype 1 pneumococci recovered from different con-
tinents. For example, consistent with an earlier study which
reported PcpA was widely distributed in French serotype 1 isolates
but absent in African serotype 1 isolates [23], we report that 82% of
European but only 2% of African serotype 1 pneumococci encoded
PcpA. This would plausibly reduce the impact of a vaccine based on
PcpA alone, as although it would provide very high coverage
against serotype 1 pneumococcal disease in Europe, it would not
protect against serotype 1 pneumococcal disease in Africa. Our
findings highlight the need to take geographic variation into
account when designing worldwide interventions strategies, as if
the distribution of a protein vaccine candidate was assessed based
on a dataset recovered from a single geographic region alone, it
may lead to an over or under estimation of global vaccine coverage.
Our results suggest a monovalent vaccine of PcpA, CbpA, PhtD and
PspC would not provide universal coverage against serotype 1
pneumococci. Multi-valent protein vaccines have been advocated
to increase coverage against meningococcal disease relative to
vaccines based on a single protein alone [24]; we therefore
investigated if a vaccine combining multiple proteins would
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quad-valent formulation based on PcpA, CbpA, PhtD and PspC
would provide the highest coverage against serotype 1 globally
(86%), 10% higher than a mono-valent vaccine based on CbpA alone
(76%). However, this would still leave a significant reservoir of ser-
otype 1 pneumococci that could potentially evade vaccine induced
immunity and which could lead to replacement disease following
global protein vaccine introduction.
SP0148, SP1912 and SP2108 showed 100% distribution in the
serotype 1 population, thus a vaccine based on one or more of
these proteins would potentially provide 100% coverage against
serotype 1 worldwide. A second requisite for an efficacious pneu-
mococcal vaccine is minimal variation of the target antigen.
SP1912 was largely conserved, with a single amino acid variant
dominating globally, which showed 100% homology to the TIGR4
reference protein. In contrast, multiple variants of SP0149 and
SP2108 were identified in the study population. The distribution
of these variants varied between continents. SP0148 variant-1
dominated in Africa and Asia, whilst SP0148 variant-2 dominated
in Europe and South America. Likewise SP2108 variant-1 was dom-
inant in Africa and Asia, whilst SP2108 variant-3 was dominant in
Europe in South America. The dominance of specific variants in the
African and Asian population that are not widely distributed in iso-
lates from either Europe or South America is consistent with whole
genome analysis of a this dataset of serotype 1 pneumococci,
which reported that serotype 1 forms four, genetically distinct lin-
eages, each of which is predominantly associated with a single con-
tinent [18].
The presence of multiple variants in the target population can
reduce the efficaciousness of a protein vaccine if the variants are
antigenically or structurally different from the protein variant on
which the vaccine is based. This can result in pneumococci encod-
ing a specific variant escaping recognition by memory T-cells fol-
lowing immunisation with the vaccine variant. SP0148 variant-3,
identified in only 2% of the study population was predicted to exhi-
bit a different antigenicity profile from the S. pneumoniae TIGR4
reference. Furthermore, analysis at the structural level suggested
that the variation identified in variant-3 might alter protein struc-
ture/function. Whilst structural analysis of SP0148 variant-4, pre-
sent in 1% of the study population, suggested that isolates
encoding this variant would likely express a non-functional pro-
tein. SP1912 variant-2 present in only 2% of the global population
was predicted to have an altered antigenicity profile to the SP1912
TIGR4. Isolates harbouring SP2108 variants-7, -8, -9 and -12 were
also predicted to express non-functional proteins. However, as
each of these variants predicted to exhibit altered antigenicity/
structural profiles only accounted for a very small proportion of
the overall population, it is unlikely that they would have an initial
impact on vaccine efficacy. Most research is now focused on a
trivalent formulation of all three proteins (SP0148, SP1912 and
SP2108), we therefore hypothesise that, if immunogenic, a vaccine
targeted against one or more of these three proteins may illicit
near universal protection against all of the variants identified
within the serotype 1 population. As stated earlier however, pro-
tein vaccine candidates aim to avoid Red Queen dynamics, i.e.
the opportunity for the pneumococcus to escape vaccine selective
pressure by targeting universally present proteins. It is feasible
that over time, the small proportion of pneumococci that already
encode the non-functional or potential ‘vaccine escape’ protein
variants may become more dominant in the population and ulti-
mately reduce long term vaccine efficacy. A further potential future
problem in employing these three proteins as protein vaccine can-
didates is that sequences with high amino acid identity to these
proteins, which are hypothesised to perform the same function,
have been identified in other Streptococcus species [25]. As such,
it is feasible that the highly recombinogenic S. pneumoniae mayexchange SP0148/SP1912/SP2108, for homologous proteins from
other co-colonising Streptococcus species in the future and will
subsequently be able to evade a vaccine based on these proteins.
Our study is limited in that the study collection was compiled as
part of an African consortium and as such features predominantly
African serotype 1 pneumococci and a fewer number of isolates
from a limited number of countries within other continents. Thus
the observations for Asia, Europe and South America serotype 1
pneumococci may be less representative of pneumococcal diver-
sity within these regions because of limited numbers of samples/-
countries included and conversely the African sites may add a
different bias as a consequence of contributing large numbers from
a few major surveillance sites. We applied a stringent QC process
to the whole genome sequences, however it is feasible that poor
genome assembly in the regions encoding vaccine targets antigens,
may have caused us to report that a vaccine candidate was absent
in an isolate, when it was actually present. Our protein modelling
and antigenicity profile analysis was based on computational
predictions, furthermore the modelling was based on secondary
structure analysis alone and the antigenicity profiling based on a
single measure of antigenicity, thus our results may not be truly
representative of protein structure and antigenicity in vitro.
Nonetheless, this analysis highlights the fact that the proposed
vaccine candidates are not universally present or conserved
amongst the serotype 1 pneumococci between different geograph-
ical regions. It is therefore imperative that genomic, structural and
antigenic variation between serotype 1 pneumococci between dif-
ferent geographical regions is taken into account when designing
vaccine interventions, in order to ensure that an intervention is
effective worldwide.
We report that within the serotype 1 pneumococcal population
worldwide, three of the seven protein vaccine candidate antigens
investigated (SP0148, SP1912, SP2108) were present in all isolates
in this study, and are highly conserved at the sequence level. These
candidates are currently in phase 2a clinical trials [26]; this study
strongly supports their inclusion in the development of vaccines
against this important pneumococcal serotype.Funding
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